Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | MC4R | P32245 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 5/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241423 | 0.88 | KMT2A (0.63) | KMT2AL3MBTL1DRD2MEN1KCNA3 | |
| SCHEMBL2241424 | 0.88 | KMT2A (0.63) | KMT2AL3MBTL1DRD2MEN1KCNA3 | |
| SCHEMBL178929 | 0.88 | KMT2A (0.63) | KMT2AL3MBTL1DRD2MEN1KCNA3 | |
| SCHEMBL555251 | 0.87 | KMT2A (0.62) | KMT2AL3MBTL1DRD2MEN1KCNA3 | |
| SCHEMBL915402 | 0.87 | KMT2A (0.65) | KMT2AL3MBTL1DRD2MEN1KCNA3 | |
| SCHEMBL1815532 | 0.87 | KMT2A (0.65) | KMT2AL3MBTL1DRD2MEN1KCNA3 | |
| SCHEMBL25299434 | 0.84 | KMT2A (0.56) | KMT2AL3MBTL1DRD2MC4RMEN1 | |
| SCHEMBL4023201 | 0.84 | DRD2 (0.60) | KMT2AL3MBTL1DRD2MEN1KCNA3 | |
| SCHEMBL1412219 | 0.83 | KMT2A (0.58) | KMT2AL3MBTL1DRD2MEN1KCNA3 | |
| SCHEMBL1412221 | 0.83 | KMT2A (0.58) | KMT2AL3MBTL1DRD2MEN1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
| EP-4384520-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023017442-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | KMT2A 1840/4885L3MBTL1 964/4885DRD2 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.